HOME >> BIOLOGY >> NEWS
Penn leads $4 million grant to study gene-environment interactions in lung cancer

PHILADELPHIA - The University of Pennsylvania School of Medicine, in association with Pennsylvania State University Medical College and Lincoln University, has received $4.2 million to study gene-environment interactions that increase the risk of lung cancer in African American and Caucasian smokers and non-smokers. The funds were awarded from Pennsylvanias share of the national tobacco settlement for 2006-2007.

The award, which was announced by Governor Rendell last month, will fund the establishment of a Center for Gene-Environment Interactions in Lung Cancer directed by Steve Whitehead, PhD, Professor of Pharmacology. The study will be conducted under the Gene-Environment Initiative of Penns Center of Excellence in Environmental Toxicology (CEET), directed by Trevor M. Penning, PhD.

Lung cancer is the leading cause of cancer deaths in the adult U.S. population. This year alone 174,500 new cases of lung cancer will be diagnosed and almost as many deaths will result, notes Penning. Eighty-five to ninety percent of all lung cancer is seen in individuals who smoke cigarettes, yet only ten-percent of those who smoke will succumb to the disease. These statistics suggest that a significant gene-environment interaction exists.

Cigarette smoke contains two major classes of cancer-causing chemicals: those derived from nicotine and those derived from polycyclic aromatic hydrocarbons (PAHs). PAHs are also produced by burning fossil fuels and are ubiquitous environmental pollutants. PAHs are present in soot that is found at relatively high concentrations in the air we breathe in urban environments, explains Penning. Exposure to environmental PAHs may also account for lung-cancer incidence in people who have never smoked.

The researchers aim to enroll and compare 600 lung-cancer patients from Philadelphia, which has high concentrations of air pollutants, and 600 patients from Hershey, Pa., which has comparatively unpolluted air. In
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
27-Apr-2007


Page: 1 2 3

Related biology news :

1. Acute sleep deprivation leads to changes in nighttime urine production for men and women
2. Biodesign Institute leads innovative project to prevent cancer
3. Screening approach leads to discovery of gene linked to breast cancer
4. Alcohol use during pregnancy leads to greater risk of extreme preterm delivery
5. Study of unexplained respiratory infections leads researchers to new virus
6. FSU leads botanical research into 21st century: Deep South Plant Specimen Imaging Project
7. Old dinosaur research leads to new honor
8. Long-term marijuana smoking leads to respiratory complaints
9. Trusting your instincts leads you to the right answer
10. Childrens Hospital researcher leads multipronged attack on infant leukemia
11. How brain injury leads to seizures, memory problems

Post Your Comments:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: